Promis Neurosciences Inc (PMN) Stock Price, Quote & News

Company Profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer'...

Industry: Biotechnology

Sector: Healthcare

Phone: 416 847 6898

Fax: 416 847 6899

Website: www.promisneurosciences.com

Address:

1920 Yonge Street, Suite 200, Toronto, Canada

JarvisFlow Nov. 21 at 3:01 PM

HC Wainwright & Co. updates rating for ProMIS Neurosciences ( $PMN ) to Buy, target set at 4.

0 · Reply

Spinaroonie Nov. 20 at 8:44 PM

$PMN

1 · Reply

Misterx69 Nov. 19 at 3:02 PM

$PMN 17 novembre special shareholders meeting for vote R/S (shares consolidati on...) at a ratio 1/5 - 1/25 https://www.sec.gov/Archives/edgar/data/1374339/0001104659-25-113978-index.html

1 · Reply

JarvisFlow Nov. 18 at 2:21 PM

Guggenheim updates rating for ProMIS Neurosciences ( $PMN ) to Buy, target set at 6 → 5.

1 · Reply

Misterx69 Nov. 15 at 10:52 AM

$PMN Good morning, can someone explain the situation regarding a possible R/S? Have they already voted? I understand that compliance must be completed by December 29, 2025.

3 · Reply

QAnonGsus Nov. 14 at 9:51 PM

$PMN here’s something. https://www.biospace.com/press-releases/promis-neurosciences-announces-third-quarter-2025-financial-results-corporate-highlights

0 · Reply

d_risk Nov. 12 at 4:17 PM

$PMN - ProMIS Neurosciences Inc. - 10Q - Updated Risk Factors PMN expands its risk disclosure on U.S. policy changes, highlighting new threats from tariffs, 2025 tax reforms, and shifting regulations that could hit costs, operations, and shareholder value. #Biotechnology #TaxReform #Tariffs #U.S.Policy #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/PMN/10-Q/2025-11-12

0 · Reply

pinupinu Nov. 12 at 3:05 PM

$PMN on the rise finally

0 · Reply

pinupinu Nov. 12 at 1:22 PM

$PMN pump … buy pump it up

0 · Reply

pinupinu Nov. 12 at 1:17 PM

$PMN P um P up the jam

0 · Reply

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

Nov 3, 2025, 4:05 PM EST - 17 days ago

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 22, 2025, 7:30 AM EDT - 4 weeks ago

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

Sep 3, 2025, 7:00 AM EDT - 2 months ago

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

Aug 13, 2025, 7:00 AM EDT - 3 months ago

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

Jul 29, 2025, 8:00 AM EDT - 4 months ago

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

Jul 28, 2025, 7:00 AM EDT - 4 months ago

ProMIS Neurosciences Announces Private Placement Financing

Jul 21, 2025, 8:00 AM EDT - 4 months ago

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

Jun 17, 2025, 7:00 AM EDT - 5 months ago

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

May 12, 2025, 7:30 AM EDT - 6 months ago

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

Mar 31, 2025, 7:00 AM EDT - 8 months ago

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

Mar 24, 2025, 7:00 AM EDT - 8 months ago

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

Mar 13, 2025, 7:00 AM EDT - 9 months ago

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

Mar 11, 2025, 7:30 AM EDT - 9 months ago

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

Feb 25, 2025, 7:00 AM EST - 9 months ago

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

Jan 29, 2025, 7:30 AM EST - 10 months ago

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 13, 2025, 10:30 AM EST - 11 months ago

ProMIS Neurosciences Issues Letter to Shareholders

Nov 14, 2024, 9:15 AM EST - 1 year ago

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

Oct 30, 2024, 8:00 AM EDT - 1 year ago

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

Sep 12, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

Sep 5, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 1, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

Jul 30, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

Jul 26, 2024, 8:35 AM EDT - 1 year ago

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Jul 26, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

May 14, 2024, 4:01 PM EDT - 1 year ago

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

Apr 30, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

Apr 9, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Apr 4, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

Apr 1, 2024, 4:15 PM EDT - 1 year ago

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Mar 11, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Feb 22, 2024, 7:00 AM EST - 1 year ago

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

Jan 22, 2024, 7:00 AM EST - 1 year ago

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Jan 3, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences, Inc. Announces Leadership Transition

Dec 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Nov 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease

Nov 14, 2023, 4:30 PM EST - 2 years ago

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Sep 8, 2023, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

Sep 6, 2023, 12:18 PM EDT - 2 years ago

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 21, 2023, 4:12 PM EDT - 2 years ago

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

Aug 14, 2023, 5:33 PM EDT - 2 years ago

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

Jul 17, 2023, 7:00 AM EDT - 2 years ago

ProMIS Showcases Preclinical Data at the Alzheimer's Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer's Pipeline

Jul 14, 2023, 7:45 AM EDT - 2 years ago

ProMIS Announces Completion of Continuance

Jul 10, 2023, 7:55 AM EDT - 2 years ago

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

Jun 30, 2023, 8:00 AM EDT - 2 years ago

ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved

Jun 29, 2023, 8:00 AM EDT - 2 years ago

CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time

May 15, 2023, 5:00 PM EDT - 2 years ago

ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

May 8, 2023, 9:00 AM EDT - 2 years ago

ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer's Disease

Apr 25, 2023, 5:00 PM EDT - 2 years ago

Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer's Disease

Apr 24, 2023, 7:30 AM EDT - 2 years ago

ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer's Disease and ALS at American Academy of Neurology Annual Meeting

JarvisFlow Nov. 21 at 3:01 PM

HC Wainwright & Co. updates rating for ProMIS Neurosciences ( $PMN ) to Buy, target set at 4.

0 · Reply

Spinaroonie Nov. 20 at 8:44 PM

$PMN

1 · Reply

Misterx69 Nov. 19 at 3:02 PM

$PMN 17 novembre special shareholders meeting for vote R/S (shares consolidati on...) at a ratio 1/5 - 1/25 https://www.sec.gov/Archives/edgar/data/1374339/0001104659-25-113978-index.html

1 · Reply

JarvisFlow Nov. 18 at 2:21 PM

Guggenheim updates rating for ProMIS Neurosciences ( $PMN ) to Buy, target set at 6 → 5.

1 · Reply

Misterx69 Nov. 15 at 10:52 AM

$PMN Good morning, can someone explain the situation regarding a possible R/S? Have they already voted? I understand that compliance must be completed by December 29, 2025.

3 · Reply

QAnonGsus Nov. 14 at 9:51 PM

$PMN here’s something. https://www.biospace.com/press-releases/promis-neurosciences-announces-third-quarter-2025-financial-results-corporate-highlights

0 · Reply

d_risk Nov. 12 at 4:17 PM

0 · Reply

pinupinu Nov. 12 at 3:05 PM

$PMN on the rise finally

0 · Reply

pinupinu Nov. 12 at 1:22 PM

$PMN pump … buy pump it up

0 · Reply

pinupinu Nov. 12 at 1:17 PM

$PMN P um P up the jam

0 · Reply

pinupinu Nov. 11 at 2:46 PM

$PMN pump up the jam

0 · Reply

pinupinu Nov. 10 at 8:33 PM

$PMN why ?

0 · Reply

MH2024 Nov. 10 at 6:19 PM

$PMN Get in early and cheap! You will not regret it!🔥

1 · Reply

MH2024 Nov. 6 at 1:26 AM

$PMN you need to hold this until spring. I think in a few months it could take off.

0 · Reply

pinupinu Nov. 3 at 5:21 PM

$PMN it’s a turd 💩

1 · Reply

pinupinu Nov. 3 at 2:40 PM

$PMN fcked again today

0 · Reply

pinupinu Nov. 3 at 2:06 PM

$PMN ready to fly today

0 · Reply

pinupinu Oct. 31 at 4:21 PM

$PMN

0 · Reply

MH2024 Oct. 30 at 8:56 PM

$PMN It’s a matter of when not if!🔥🚀

0 · Reply

TraderMain Oct. 27 at 3:32 PM

$PMN This should be at .73 easily, management are frickin MORONS, yes vote NO! No news and your product is FDA fast tracked?? Terrible management 👎

1 · Reply

asymmetricvalue Oct. 26 at 7:28 PM

$PMN How clear do we have to make it? Vote NO

0 · Reply

asymmetricvalue Oct. 23 at 1:37 PM

$PMN VOTE NO

1 · Reply

Market Cap	22.35M
Revenue (ttm)	0.00
Net Income (ttm)	2.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	228,490
Avg Vol	647,474
Day's Range	N/A - N/A
Shares Out	53.81M
Stochastic %K	31%
Beta	-0.22
Analysts	Strong Sell
Price Target	$6.10